1. Sathe PM, Tsong Y, Shah VP. In-vitro dissolution profile comparison: statistics and analysis, model dependent approach. Pharm Res. 1996;13(12):1799–803.
2. Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison—statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15(6):889–96.
3. U.S. Food and Drug Administration. Guidance for industry dissolution testing of immediate release solid oral dosage forms. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). August 1997; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070237.pdf Accessed 15 Feb 2016.
4. U.S. Food and Drug Administration. Guidance for industry: immediate release solid oral dosage forms. Scale-up and post-approval changes: chemistry, manufacturing and controls, in vitro dissolution testing, and in vivo bioequivalence documentation [SUPAC-IR]. November 1995; http://www.fda.gov/downloads/Drugs/.../Guidances/UCM070636.pdf Accessed 15 Feb 2016.
5. European Medicines Agency. CPMP/EWP/QWP/1401/98 Rev. 1 Committee for Medicinal Products for Human Use (CHMP). 2010; Guideline on the Investigation of Bioequivalence. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (2010) Accessed 15 Feb 2016.